Embecta (EMBC) Competitors

Axonics (NASDAQ:AXNX) and Embecta (NASDAQ:EMBC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, community ranking, institutional ownership and dividends.

Which has better earnings & valuation, AXNX or EMBC?

Embecta has higher revenue and earnings than Axonics. Axonics is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axonics	$366.38M	9.90	-$6.09M	-$0.12	-591.45
Embecta	$1.12B	0.75	$70.40M	$1.20	12.18

Do analysts prefer AXNX or EMBC?

Axonics presently has a consensus target price of $71.00, suggesting a potential upside of 0.03%. Embecta has a consensus target price of $12.00, suggesting a potential downside of 17.92%. Given Axonics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Axonics is more favorable than Embecta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axonics	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Embecta	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Which has more risk and volatility, AXNX or EMBC?

Axonics has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Embecta has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.

Does the MarketBeat Community believe in AXNX or EMBC?

Axonics received 174 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 66.41% of users gave Axonics an outperform vote while only 0.00% of users gave Embecta an outperform vote.

Company	Underperform	Outperform
Axonics	Outperform Votes 174 66.41%	Underperform Votes 88 33.59%
Embecta	Outperform Votes No Votes	Underperform Votes 14 100.00%

Do insiders and institutionals believe in AXNX or EMBC?

99.5% of Axonics shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 1.9% of Axonics shares are owned by insiders. Comparatively, 0.3% of Embecta shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Is AXNX or EMBC more profitable?

Embecta has a net margin of 6.23% compared to Axonics' net margin of -1.31%. Axonics' return on equity of 0.36% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axonics	-1.31%	0.36%	0.31%
Embecta	6.23%	-19.09%	12.27%

Does the media refer more to AXNX or EMBC?

In the previous week, Axonics had 3 more articles in the media than Embecta. MarketBeat recorded 6 mentions for Axonics and 3 mentions for Embecta. Embecta's average media sentiment score of 0.62 beat Axonics' score of 0.59 indicating that Embecta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axonics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Embecta	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Axonics beats Embecta on 9 of the 17 factors compared between the two stocks.